Welcome to the Lilly Scientific Information Page for OW 2025
Obesity Week
Atlanta, Georgia
Quicklinks
See how Lilly supports external requests for provision of study drug and/or financial support.
To stay informed on the latest science and innovation, please be sure to follow us on Twitter/X.
To receive the latest science and innovation, please be sure to follow us on LinkedIn.
Disclosures
TUESDAY
- Disease State: Obesity
- Presented by: Rodolfo Galindo
- Molecule(s): Tirzepatide
Tirzepatide vs Semaglutide in Participants with Prediabetes: A Post Hoc Analysis of the SURMOUNT-5 Trial
Trial(s) Overview:
TUESDAY
- Disease State: Obesity
- Presented by: Georgios Dimitriadis
- Molecule(s): Tirzepatide
Comparative Effectiveness of 6 Months of Tirzepatide vs. Semaglutide Treatment for Obesity Management
Trial(s) Overview:
Not Applicable
TUESDAY
- Disease State: Obesity
- Presented by: Chanadda Chinthammit
- Molecule(s): Tirzepatide
Real-World Effectiveness of Tirzepatide Among Individuals with Obesity or Overweight
Trial(s) Overview:
Not Applicable
TUESDAY
- Disease State: Obesity in Diabetes
- Presented by: Ryan Griffin
- Molecule(s): Tirzepatide
Number Needed to Treat to Prevent Diabetes and Cost Savings Based on SURMOUNT-1 Extension
Trial(s) Overview:
TUESDAY
- Disease State: Obesity in Diabetes
- Presented by: Ariana Chao
- Molecule(s): Tirzepatide
Changes in Physical Function by Degree of Improvement in Inflammatory Biomarkers in SURMOUNT-2
Trial(s) Overview:
TUESDAY
- Disease State: Obesity
- Presented by: Theresa Hunter Gibble
- Molecule(s): Orforglipron
Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) in Adolescents with Obesity or Overweight
Trial(s) Overview:
Not Applicable
WEDNESDAY
- Disease State: Obesity
- Presented by: Daniel Briere
- Molecule(s): Eloralintide
Eloralintide (LY3841136), a Selective Amylin Analog, Improves Insulin Sensitivity Independent of Weight Loss in Diet-induced Obese Rats
Trial(s) Overview:
Not Applicable
WEDNESDAY
- Disease State: Obesity
- Presented by: Alpana Shukla
- Molecule(s): Tirzepatide
Improved Health-related Quality of Life with Tirzepatide vs Semaglutide: An Analysis of SURMOUNT-5
Trial(s) Overview:
WEDNESDAY
- Disease State: Obesity
- Presented by: Alpana Shukla, Sean Wharton, Deborah Horn, Nasreen Alfaris, Donna Ryan
- Molecule(s): Orforglipron
ObesityWeek® 2025 Corporate Oral Session: Advancing Treatment for Obesity with Orforglipron, the First Oral Non-peptide GLP-1 Receptor Agonist: Phase 3 Findings
Trial(s) Overview:
THURSDAY
- Disease State: Obesity
- Presented by: Stanley Hsia, Harold Bays, Liana Billings
- Molecule(s): Eloralintide
ObesityWeek® 2025 Corporate Oral Session: Eloralintide Phase 2 in Obesity: Study Design, Safety, and Efficacy
Trial(s) Overview:
THURSDAY
- Disease State: Morbidity and Mortality in Obesity
- Presented by: Alexandra Lin
- Molecule(s): Tirzepatide
Identifying Best Practices in Successful Cardiometabolic Care Programs
Trial(s) Overview:
Not Applicable
THURSDAY
- Disease State: Obesity
- Presented by: Elizabeth Eby
- Molecule(s): Tirzepatide
Real-World Treatment Patterns of Tirzepatide Vials for Obesity via the LillyDirect Program
Trial(s) Overview:
Not Applicable
THURSDAY
- Disease State: Obesity
- Presented by: Deborah Horn
- Molecule(s): Tirzepatide
Association of Weight Reduction With Weight Cycling Parameters: A SURMOUNT-5 Trial Post Hoc Analysis
Trial(s) Overview:
THURSDAY
- Disease State: Obstructive Sleep Apnea
- Presented by: Shraddha Shinde
- Molecule(s): Tirzepatide
Early Real-World use of Tirzepatide Among Individuals with Moderate-to-Severe OSA and Obesity: Results from Optum Market Clarity Integrated Clinical and Claims Database
Trial(s) Overview:
Not Applicable
THURSDAY
- Disease State: Obstructive Sleep Apnea
- Presented by: Jeremy McConnell
- Molecule(s): Tirzepatide
Obstructive Sleep Apnea (OSA) Measures by Body Weight Reduction Magnitudes from the SURMOUNT-OSA Trials: Post-Hoc Analyses
Trial(s) Overview:
THURSDAY
- Disease State: Obesity
- Presented by: Theresa Hunter Gibble
- Molecule(s): Orforglipron
Qualitative Interviews to Develop an Obesity Medication Satisfaction Questionnaire
Trial(s) Overview:
Not Applicable
THURSDAY
- Disease State: Obesity
- Presented by: Christy Houle
- Molecule(s): Orforglipron
Patients' Preferences for Attributes of Obesity Management Medications
Trial(s) Overview:
Not Applicable
THURSDAY
- Disease State: Obesity
- Presented by: Melissa Thomas
- Molecule(s): Retatrutide
Retatrutide Alters Circulating Proteomic Markers Related to Lipid Metabolism
Trial(s) Overview:
Not Applicable
THURSDAY
- Disease State: Obesity
- Presented by: Meghana Tallam
- Molecule(s): Retatrutide
Navigating the Changing Landscape of Obesity Care: Insights from a Retrospective Observational Study
Trial(s) Overview:
Not Applicable
THURSDAY
- Disease State: Osteoarthritis
- Presented by: Magaly Perez-Nieves
- Molecule(s): Retatrutide
Exploring the Impact of Knee Osteoarthritis on Life Aspects of Individuals with Overweight or Obesity
Trial(s) Overview:
Not Applicable
FRIDAY
- Disease State: Obesity
- Presented by: Stanley Hsia
- Molecule(s): Mazdutide
Mazdutide (LY3305677) in Participants with Obesity or Overweight: A Phase 2 Dose-Finding Study
Trial(s) Overview:
To receive the latest science and innovation from LillyMedical, be sure to follow us via our Twitter handle @LillyMedical. See our community guidelines.
Contact Us
Call us
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)